Malate Dehydrogenase (MDH) is an enzyme that plays a key role in cellular metabolism and belongs to the NAD-dependent dehydrogenase family. Malate Dehydrogenase (MDH) catalyzes the reversible conversion between malate and oxaloacetate. There are multiple subtypes of MDH. In eukaryotes, there are mainly cytoplasmic MDH1, mitochondrial MDH2, and MDH present in peroxisomes, glyoxysomes, and chloroplasts; there is only one MDH in prokaryotes such as Escherichia coli. MDH1 is closely related to the proliferation and survival of tumor cells, and its high expression is associated with a poor prognosis of non-small cell lung cancer. MDH1 plays an important role in replenishing cytoplasmic NAD to support glycolysis during cell proliferation, and together with lactate dehydrogenase (LDH), maintains the intracellular NAD supply; in cardiovascular disease research, it was found that changes in its activity are related to energy metabolism, oxidative stress and other processes in cardiac tissue. In addition, MDH participates in important metabolic pathways such as the tricarboxylic acid cycle, gluconeogenesis, and amino acid synthesis, and plays a role in different cellular compartments. For example, MDH transports reducing equivalents between the cytoplasm and mitochondria through the malate-aspartate shuttle, maintaining cellular energy metabolism and normal physiological functions[1][2][3][4][5][6].
MDH1-IN-1 是一种选择性 MDH1 抑制剂,对人源靶点的 IC50 为 6.79 μM,具有体内抗肿瘤功效,可用于结直肠癌的研究。
MDH1-IN-2 (Compound 7c) 是一种选择性 MDH1 抑制剂,对 MDH1 和 MDH2 的 IC50 分别为 2.27 和 27.47 μM,其通过抑制 MDH1 介导的 2-Ketoglutaric acid (MS-Z45936) 向 α-Hydroxyglutaric acid (MS-W37837) 转化来减少 ROS 生成,进而抑制 2-Ketoglutaric acid (MS-Z45936) 诱导的铁死亡 (ferroptosis)。
MDH1/2-IN-1 是一种 MDH1/2 抑制剂(IC50 分别为 1.07 μM 和 1.06 μM),可抑制线粒体呼吸和 HIF-1α 通路,显示出显著的抗肿瘤潜力,为开发靶向癌症代谢的药物提供了新的方向。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号